Johnson and Johnson

Johnson & Johnson is the world's largest and most broadly diversified healthcare company, and — following the 2023 separation of its Consumer Health business and the announced separation of its Orthopaedics business — it is in the late stages of a decade-long transformation from a three-sector conglomerate into a focused, science-led enterprise operating across two segments: prescription medicines and interventional medical technology. The company's stated positioning is that of a comprehensive healthcare innovation platform capable of addressing disease across the full continuum, from pharmacological intervention to procedural and device-based treatment, with self-declared leadership ambitions concentrated in six businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. Financially, the company is defined by three characteristics that few peers share simultaneously: scale (FY2025 revenue of USD 94.2 billion, on track to exceed USD 100 billion in FY2026 for the first time in a 140-year corporate history), balance-sheet quality (one of only three U.S. corporates carrying both a Moody's Aaa and an S&P AAA long-term issuer rating), and dividend durability (64 consecutive years of dividend increases as of 2026). The structural counterweights are equally distinctive: a decade-long talc product-liability overhang now moving toward resolution, an accelerating patent-cliff sequence beginning with STELARA and extending to DARZALEX later this decade, and a MedTech segment whose margin profile has compressed materially since 2021.

Employee headcount trend (FTE positions):

The FY2023 figure is drawn from the FY2023 Form 10-K, which did not separately disaggregate headcount from FTE; the two rows are therefore identical for that year and the FY2023 headcount figure should be treated as approximate.

Geographic distribution of the workforce as disclosed in the FY2025 annual report comprises four regions — North America, EMEA, Asia Pacific and Latin America — with shares of approximately 35.9%, 27.8%, 19.5% and 16.8%. The precise region-to-percentage mapping is not unambiguously recoverable from the extracted disclosure and should be verified against the source document before use in a client deliverable.

The company's own characterisation. In the FY2025 Form 10-K, Johnson & Johnson describes itself as a holding company whose operating subsidiaries conduct business in virtually all countries of the world, with a primary focus on products related to human health and well-being. It positions its dual-segment structure as a source of unique advantage, arguing that expertise spanning both medicines and medical technology allows it to innovate across the full spectrum of healthcare solutions. The Chief Operating Decision Maker is the Chief Executive Officer; strategy and priorities are set by a ten-member Executive Committee, within whose parameters U.S. and international operating-company management teams retain responsibility for their own strategic plans and day-to-day operations.

Independent characterisation. Johnson & Johnson is best understood not as a single business but as two structurally different businesses sharing a balance sheet, a capital-allocation function and a brand.

The Innovative Medicine segment (64.1% of FY2025 revenue) is a classical research-based biopharmaceutical operation. Its economics are those of a patent-protected specialty portfolio: gross margins well in excess of the corporate average, R&D intensity in the mid-teens as a share of segment sales, segment pre-tax margins of 36.9% in FY2025, and revenue that is highly concentrated in a small number of large molecules. Three products — DARZALEX/DARZALEX FASPRO, STELARA and TREMFYA — accounted for approximately 15.0%, 6.5% and 5.5% of total company revenue in FY2025 respectively, or roughly 27% of consolidated sales from three franchises. The revenue model is almost entirely product sales of prescription medicines distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals; there is no meaningful subscription or service component, and licensing income is disclosed as immaterial relative to product revenue. The segment carries substantial inbound royalty obligations that function economically as a revenue-sharing arrangement: Genmab A/S receives 12–20% of total DARZALEX net sales, amounting to approximately USD 2.4 billion in fiscal 2025 and USD 2.0 billion in fiscal 2024; third-party licensors receive approximately 5.0% of TREMFYA net sales.

The MedTech segment (35.9% of FY2025 revenue) is a procedural-technology business. Its economics are those of a capital-and-consumables medical device operation: lower gross margin, heavy field-force and clinical-evidence cost, higher fixed manufacturing intensity, and segment pre-tax margins of 12.2% in FY2025 — roughly one third of the Innovative Medicine level. Demand is driven by procedure volumes rather than prescription volumes, which makes the segment sensitive to hospital capital budgets, elective-procedure recovery, surgeon adoption cycles and, in China, government volume-based procurement tendering. Revenue mixes durable capital equipment (electrophysiology mapping consoles, robotic platforms, VELYS robotic-assisted surgical solutions) with high-recurrence consumables (catheters, staplers, sutures, contact lenses, intraocular lenses), producing a razor-and-blade dynamic in the fastest-growing sub-franchises.

Value chain position. The company sits at the innovation and manufacturing end of the healthcare value chain, upstream of distribution and dispensing. It operates 63 owned or leased manufacturing facilities and sources from thousands of suppliers. Concentration in the customer base is material and disclosed: in fiscal 2025 three wholesalers distributing products for both segments represented approximately 21.8%, 15.5% and 11.1% of total gross revenues — 48.4% in aggregate. The 10-K does not name these wholesalers. In fiscal 2024 the equivalent figures were 20.5%, 15.6% and 12.3%.

Customer types and end-markets. Innovative Medicine sells into retail pharmacy, hospital pharmacy, specialty distribution and government procurement channels, with reimbursement determined by government programmes (Medicare, Medicaid, national health systems), private insurers and pharmacy benefit managers. MedTech sells into hospitals, ambulatory surgical centres, eye-care professional practices and specialty clinics, with purchasing decisions made by clinicians in conjunction with hospital value-analysis committees and group purchasing organisations. End-markets served span oncology (prostate, hematologic malignancies, lung, bladder), immunology (rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis), neuroscience (mood disorders, neurodegenerative disorders, schizophrenia), pulmonary arterial hypertension, infectious disease (HIV), cardiovascular and metabolism (thrombosis, diabetes, macular degeneration), interventional cardiology and electrophysiology, orthopaedic reconstruction and trauma, general and advanced surgery, and vision correction and cataract surgery.

Revenue concentration by geography. Approximately 43% of fiscal 2025 sales occurred outside the United States: roughly 23% in Europe, 5% in the Western Hemisphere excluding the U.S., and 15% in Asia-Pacific and Africa. Four markets — Argentina, Turkey, Venezuela and Egypt — are accounted for as highly inflationary economies because three-year cumulative inflation surpassed 100%.

Innovation dependency. New products introduced within the past five years accounted for approximately 25% of fiscal 2025 sales — a metric management uses as a proxy for portfolio renewal capacity and one that is directly relevant to the STELARA-to-TREMFYA-to-ICOTYDE succession dynamic described in Section 22.

10.1 Stated strategy

The company's strategic articulation, as set out in the FY2025 annual report and the 2026 proxy statement, rests on four themes.

First, portfolio concentration on six businesses. Management repeatedly frames the enterprise around Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, describing fiscal 2025 as the start of a new era of accelerated growth driven by expanding leadership in each. The corollary is exit from anything outside those six: Consumer Health in 2023, orthopaedics from 2027, and the fiscal 2023–2026 restructuring programmes that exited infectious disease and vaccine R&D, orthopaedic product lines and non-strategic surgery lines.

Second, dual-segment breadth as a differentiator. Management argues that spanning both medicines and medical technology gives the company depth and scale unavailable to single-modality competitors, positioning it to innovate across the full spectrum of healthcare solutions.

Third, scale investment in innovation, both internal and external. More than USD 32 billion was invested in fiscal 2025 across R&D and inorganic innovation, comprising the USD 14.7 billion R&D line, the Intra-Cellular and Halda acquisitions, and 40 further collaborations, partnerships and licences.

Fourth, a stated line of sight to double-digit revenue growth by the end of the decade. This is the single most consequential management claim and is reaffirmed at each earnings call. The mechanism, as articulated by the CFO and on the Q1 2026 call, is the scaling of recent launches combined with the roll-off of DARZALEX royalties in 2029.

10.2 Announced initiatives, last 24 months

10.3 Management financial targets and guidance

The 29 July 2026 revision reflects USD 0.64 of dilution from the Firefly acquisition (USD 0.46) and the Sail transaction (USD 0.18). Combined 2027 dilution is guided at approximately USD 1.36 — USD 0.08 from Firefly and USD 1.28 from Sail, assuming milestone achievement and exercise of the acquisition option. Adjusted pre-tax operating margin expansion for fiscal 2026 was raised at the July update to approximately 75 basis points from at least 50 basis points. Fiscal 2026 contains a 53rd week, weighting Q4 contribution.

Sustainability metrics are integrated into executive compensation, and third-party assurance of environmental data is being expanded.

Twenty-eight products and platforms each generated more than USD 1 billion in annual sales in fiscal 2025, with Shockwave and CARVYKTI joining that cohort during the year.

5.1 Innovative Medicine — Oncology (FY2025 worldwide sales USD 25,380 million, +22.1% reported, +20.9% operational)

• DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) — anti-CD38 monoclonal antibody for multiple myeloma; FASPRO additionally approved for light chain (AL) amyloidosis and, from Q4 2025, as the first and only FDA-approved treatment for high-risk smouldering multiple myeloma. The company's largest product at approximately 15.0% of total revenue. Compound patent families expire in the United States in 2029; European compound/use protection in selected countries extends to 2031/2032. Genmab royalty 12–20% of net sales.
• ERLEADA (apalutamide) — next-generation androgen receptor inhibitor for prostate cancer. A Phase 3 study reported in Q2 2026 showed significant reduction in metastasis or death when given before and after surgery in localised high-risk disease. Named on the CMS Selected Drug list for 2028 under the Inflation Reduction Act (published January 2026).
• CARVYKTI (ciltacabtagene autoleucel) — BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma, developed and commercialised with Legend Biotech. Described by the company as the most successful cell therapy launch to date, with more than 10,000 patients treated across 14 markets; 2.5-year data show durable treatment-free remissions with earlier-line use.
• RYBREVANT (amivantamab) / RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) / LAZCLUZE (lazertinib) — EGFR bispecific antibody plus brain-penetrant EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer. FDA approval of the subcutaneous FASPRO formulation in combination with LAZCLUZE (Q4 2025) delivers the shortest administration time for a first-line combination regimen. Expansion data reported in colorectal and head-and-neck cancer.
• TECVAYLI (teclistamab-cqyv) and TALVEY (talquetamab-tgvs) — BCMA- and GPRC5D-directed bispecific T-cell engagers for heavily pre-treated multiple myeloma. The Phase 3 MajesTEC-3 study supports TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line; TECVAYLI monotherapy demonstrated superior progression-free and overall survival as early as first relapse.
• IMBRUVICA (ibrutinib) — BTK inhibitor for B-cell malignancies and chronic graft-versus-host disease; co-developed and co-commercialised in the U.S. with Pharmacyclics LLC, an AbbVie company. In structural decline; included on the initial CMS Selected Drug list.
• ZYTIGA (abiraterone acetate) — prostate cancer; genericised and in terminal decline.
• INLEXZO (gemcitabine intravesical system) — drug-releasing intravesical system for BCG-unresponsive high-risk non-muscle-invasive bladder cancer, approved in 2025; reported 74% disease-free survival at one year in papillary-only NMIBC. Positioned as an alternative to cystectomy.
• AKEEGA (niraparib and abiraterone acetate) — approved in Q4 2025 as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer, with a 54% reduction in disease progression versus standard of care.

5.2 Innovative Medicine — Immunology (FY2025 worldwide sales USD 15,728 million, −11.8% reported)

• STELARA (ustekinumab) — IL-12/23 inhibitor for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. The company's second-largest product at 6.5% of total revenue, now in accelerating biosimilar erosion; it created an approximately 1,040 basis-point drag on Innovative Medicine operational growth in fiscal 2025 and 760 basis points in Q2 2026. On the initial CMS Selected Drug list, though CMS has indicated it will be removed from that list beginning in 2027.
• TREMFYA (guselkumab) — IL-23 inhibitor and the designated successor franchise. Third-largest product at 5.5% of total revenue; the fastest-growing IL-23 therapy in the U.S.; the first and only IL-23 inhibitor with a fully subcutaneous regimen for both ulcerative colitis and Crohn's disease; two-year Crohn's remission data reported; the only IL-23 inhibitor shown to substantially inhibit structural joint damage in active psoriatic arthritis, with an FDA label expansion granted in Q2 2026; also the first IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease. Composition patent family projected to expire in the United States in 2031; aggregate third-party royalty approximately 5.0% of net sales.
• ICOTYDE (icotrokinra) — approved 18 March 2026; the first and only targeted oral peptide that blocks the IL-23 receptor, for moderate-to-severe plaque psoriasis in adults and patients 12 and older weighing at least 40 kg. Phase 3 ICONIC programme in approximately 2,500 patients; taken once daily on waking, 30 minutes before food. Jointly discovered and developed under a licence and collaboration agreement with Protagonist Therapeutics. Management reported over 1,500 prescriptions written and 1,000 unique prescribers engaged within weeks of approval, and the CEO has described it as potentially one of the company's largest products ever. Supported by the ICOTYDE withMe patient access programme.
• SIMPONI / SIMPONI ARIA (golimumab) — subcutaneous and intravenous anti-TNF for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis and polyarticular juvenile idiopathic arthritis; grew 21.8% in fiscal 2025, largely on international strength.
• REMICADE (infliximab) — anti-TNF for immune-mediated inflammatory diseases; returned to growth in fiscal 2025 (+10.2%) on U.S. contracting dynamics.
• IMAAVY (nipocalimab-aahu) — FcRn blocker approved for generalized myasthenia gravis, with more than two years of sustained disease control demonstrated in a broad gMG population and a head-to-head trial against an alternative FcRn blocker underway. FDA Priority Review granted in Q2 2026 for warm autoimmune hemolytic anemia, a disease with no currently approved therapies. Phase 2 data reported in systemic lupus erythematosus and, published in The Lancet, in Sjögren's disease.
• JNJ-4804 — investigational co-antibody therapy for refractory inflammatory bowel disease, with data reported in Q2 2026 in ulcerative colitis and Crohn's disease.

5.3 Innovative Medicine — Neuroscience (FY2025 worldwide sales USD 7,837 million, +10.1% reported)

• CAPLYTA (lumateperone) — acquired with Intra-Cellular Therapies; approved for schizophrenia, bipolar depression, and — in Q4 2025 — as adjunctive therapy for major depressive disorder. An sNDA for prevention of relapse in schizophrenia was approved in Q2 2026. Network meta-analysis published in Q2 2026 positioned it as showing the greatest improvement across key efficacy outcomes among adjunctive MDD treatments. Contributed 1.2 percentage points of Innovative Medicine operational growth in fiscal 2025.
• SPRAVATO (esketamine) nasal spray — for treatment-resistant depression and for depressive symptoms in MDD with suicidal ideation. More than 200,000 patients treated worldwide; grew 67.8% in Q4 2025 and was cited by management as a principal Neuroscience growth driver in fiscal 2025 and H1 2026. The precise FY2025 worldwide sales figure for SPRAVATO was not captured in this review and should be confirmed against the earnings supplement.
• INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate) — long-acting injectable antipsychotics for schizophrenia and schizoaffective disorder.
• CONCERTA (methylphenidate HCl extended-release) — ADHD; in decline, with U.S. sales down 38.6% in fiscal 2025.

5.4 Innovative Medicine — Pulmonary Hypertension, Infectious Disease, Cardiovascular & Metabolism

• OPSUMIT (macitentan) / OPSYNVI (macitentan and tadalafil) — endothelin receptor antagonist monotherapy and fixed-dose combination for long-term treatment of pulmonary arterial hypertension.
• UPTRAVI (selexipag) — the only approved oral and intravenous selective IP receptor agonist targeting the prostacyclin pathway in PAH.
• XARELTO (rivaroxaban) — oral Factor Xa inhibitor for DVT/PE prophylaxis and treatment, stroke prevention in non-valvular atrial fibrillation, major cardiovascular event reduction in CAD and PAD, and paediatric thromboprophylaxis including post-Fontan. On the initial CMS Selected Drug list, with CMS indicating removal from 2027.
• HIV portfolio — EDURANT (rilpivirine), PREZISTA (darunavir), PREZCOBIX/REZOLSTA (darunavir/cobicistat) and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single-tablet regimen.

Segment-level fiscal 2025 revenue for Pulmonary Hypertension, Infectious Disease and Cardiovascular & Metabolism was not separately captured in this review; the FY2025 earnings supplement discloses these franchises.

5.5 MedTech portfolio and franchise revenue

Cardiovascular. The Biosense Webster electrophysiology platform comprises the CARTO 3 mapping system (with CARTOSOUND SONATA debuted at HRS 2026), the THERMOCOOL SMARTTOUCH SF radiofrequency ablation catheter family — including a Dual Energy version approved by FDA in Q2 2026 and CE-marked earlier — and the VARIPULSE pulsed-field ablation platform, used to treat more than 40,000 atrial fibrillation patients, with VARIPULSE Pro approved in Europe in Q1 2026 carrying a pulse sequence five times faster. The investigational OMNYPULSE catheter reported positive three-month data. A landmark head-to-head pulsed-field ablation trial in persistent atrial fibrillation was launched in Q2 2026. Abiomed supplies the Impella family of percutaneous heart pumps (Impella CP, Impella 5.5 with SmartAssist, Impella RP) for cardiogenic shock and high-risk PCI. Shockwave supplies intravascular lithotripsy catheters for calcified coronary and peripheral artery disease, with the C2 Aero coronary IVL catheter launched globally in Q2 2026. Neurovascular products address stroke and related conditions, including the TRUFILL n-BCA Liquid Embolic System, FDA-approved in Q4 2025 for symptomatic chronic subdural hematoma.

Surgery. The Ethicon portfolio spans endocutters and stapling (including the ETHICON 4000 Stapler, launched in 2025 and CE-marked in Q2 2026), advanced energy devices, wound closure (the principal growth driver in fiscal 2025 and H1 2026), biosurgery (including ETHIZIA, anticipated for approval in 2026), and open, laparoscopic and robotic instrumentation. OTTAVA, the world's first table-integrated soft-tissue robotic surgical system, received FDA De Novo authorization on 22 July 2026 for multiple general-surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication and hiatal hernia repair. Mentor supplies breast aesthetics and reconstruction products.

Orthopaedics (DePuy Synthes). Hip and knee reconstruction (ATTUNE knee system; the VELYS Robotic-Assisted Solution driving knee pull-through), trauma fixation (the largest single Orthopaedics platform at USD 3.1 billion), spine, sports medicine and shoulders. A two-year restructuring exiting selected markets and product lines was substantially completed in Q4 2025. In Q2 2026 DePuy Synthes agreed to acquire miniature radiofrequency tracking technology for its joint reconstruction portfolio and entered an exclusive U.S., Canada and Australia distribution agreement for CGBIO's NOVOSIS bone graft product.

Vision. The ACUVUE contact lens family, including the ACUVUE OASYS 1-Day franchise and the ACUVUE OASYS MAX 1-Day line extended in 2025 to astigmatism and presbyopia. The TECNIS premium intraocular lens range for cataract surgery, including TECNIS Odyssey — described by the company as the fastest-growing IOL in the U.S. — and TECNIS PureSee, approved for U.S. cataract patients in Q1 2026 with availability expanded in Q2 2026. More than USD 1 billion has been committed to strengthen U.S. vision manufacturing in Jacksonville, Florida.

Pricing model. The company does not disclose product-level pricing. Innovative Medicine pricing is realised net of rebates, returns and promotional allowances — accrued rebates, returns and promotions on the balance sheet grew from USD 12,095 million in 2021 to USD 19,124 million in 2025, a 58% increase against 20% revenue growth on an as-reported basis, which is a direct measure of intensifying gross-to-net pressure. Consolidated price contributed −3.1% to fiscal 2025 revenue growth against +8.4% from volume.

Basis of presentation. FY2021 and FY2022 are presented as originally reported in the respective Form 10-K filings and therefore include the Consumer Health business; FY2023 onward reflect continuing operations. Restated continuing-operations net sales were USD 78,738 million (FY2021) and USD 79,990 million (FY2022).

6.1 Income statement

Depreciation and amortisation for FY2021 and FY2022 is derived from disclosed segment-level D&A reconciled to the disclosed consolidated range and should be treated as approximate; FY2023–FY2025 are as reported in the consolidated statement of cash flows. Other income/(expense), net for FY2021–FY2023 is derived from disclosed common-size percentages applied to reported sales. Adjusted net earnings for FY2021–FY2023 on a comparable post-Kenvue basis were not captured in this review and are shown as zero rather than estimated.

6.2 Per-share data

Weighted average diluted shares for FY2021–FY2023 are approximate, derived from reported net earnings and EPS; FY2024 and FY2025 (2,429.4 million in both years) are as disclosed.

6.3 Margin analysis

Revenue CAGR FY2021–FY2025: 4.6% on the continuing-operations basis; 0.1% on the as-reported basis (the difference is the Kenvue separation).

Commentary on trends and inflections.

Gross margin. The 120 basis-point contraction in fiscal 2025 to 67.9% reflects three converging pressures: adverse mix as high-margin STELARA revenue is replaced by lower-margin or newly launched products; the growing weight of MedTech, which carries a structurally lower gross margin; and unfavourable currency in cost of products sold. Cost of products sold rose 10.1% against 6.0% revenue growth. This is the single most important operating metric to monitor, because the entire double-digit-growth thesis assumes mix improves rather than deteriorates as launches scale.

Operating margin. The 340 basis-point expansion in fiscal 2025 to 26.8% is almost entirely an R&D artefact. R&D fell 14.9% year over year, from USD 17,232 million to USD 14,665 million, because fiscal 2024 carried the USD 1.25 billion Yellow Jersey acquired-IPR&D charge and other one-off programme costs. Normalising for that, underlying R&D spend was broadly flat and operating leverage was modest. Management has guided fiscal 2026 to approximately 75 basis points of adjusted pre-tax operating margin expansion, raised from at least 50 basis points at the Q1 2026 update.

Below the operating line. The fiscal 2025 pre-tax result is dominated by a single item: other income of USD 7,209 million, driven by the approximately USD 7.0 billion talc reserve reversal recorded in Q1 2025. Fiscal 2024's other expense of USD 4,694 million was driven by approximately USD 5.1 billion of talc charges and a USD 0.4 billion loss on the Kenvue share exchange. On a GAAP basis, therefore, the 90.6% growth in fiscal 2025 net earnings is not an operating outcome. The adjusted series is the appropriate comparison: adjusted net earnings grew 8.1% to USD 26,215 million and adjusted diluted EPS grew 8.1% to USD 10.79.

Interest. Net interest has swung from a USD 577 million net income position in fiscal 2024 to a USD 85 million net income position in fiscal 2025 as cash balances were deployed into acquisitions and gross debt was increased. Interest expense has risen more than fivefold since fiscal 2021, from approximately USD 188 million to USD 970 million.

Tax. The effective rate has normalised upward from an anomalously low 8.3% in fiscal 2021 to 17.7% in fiscal 2025, converging with the adjusted effective rate of 17.3%. Q4 2025 carried a negative 3.0% GAAP effective rate on discrete tax items.

6.4 Balance sheet

Marketable securities for FY2023 and FY2024, and inventories and goodwill for FY2021–FY2024, are derived from disclosed aggregates and narrative disclosure and should be verified against the source filings before use in a valuation model. Cash and cash equivalents, current assets, all liability lines, equity and total assets are as reported. Net debt is computed as total debt less cash and cash equivalents only; including marketable securities, net debt was approximately USD 2.1 billion in FY2021 and approximately USD 27.8 billion in FY2025.

6.5 Cash flow

FY2022 capex is derived from disclosed free cash flow and operating cash flow and is approximate. FY2022 acquisitions net of cash acquired (Abiomed) is approximate and was not verified against the primary filing in this review; the disclosed narrative states acquisitions exceeded USD 17,000 million in 2022 and 2024. FY2021 and FY2023 acquisitions net of cash acquired were immaterial or nil as disclosed. FY2021 net cash used by investing activities was not captured in this review and is shown as zero rather than estimated.

Commentary. Operating cash flow has been remarkably stable in a narrow USD 21.2–24.5 billion band across five years, which is the most persuasive single fact about the durability of the underlying business. Free cash flow has been equally stable at USD 17.2–19.8 billion. What has changed radically is the use of that cash. Between fiscal 2021 and fiscal 2025 the company shifted from a net-cash-accumulating posture (net debt of approximately USD 2 billion including marketable securities at year-end 2021) to a net-debt position of approximately USD 28 billion, with USD 49.9 billion deployed on acquisitions across 2022, 2024 and 2025 alone. Dividends have grown steadily but modestly (12.2% cumulative over four years), while buybacks have been episodic, ranging from USD 2.4 billion to USD 6.0 billion annually with no fixed authorisation disclosed as outstanding at year-end 2025.

Fiscal 2025 free cash flow conversion — free cash flow of USD 19,698 million against adjusted net earnings of USD 26,215 million — was 75%, a level that reflects both elevated capital expenditure (USD 4.8 billion, the highest in the period, tracking the USD 55 billion U.S. investment programme) and a USD 5.7 billion working-capital drag from the decrease in other current and non-current liabilities, which is consistent with talc-related cash outflows.

H1 2026 free cash flow was approximately USD 8,700 million, up from USD 6,214 million in H1 2025.

6.6 Ratio analysis

Return on equity and return on assets for FY2023 are inflated by the USD 21.0 billion Kenvue separation gain and are not comparable. Return on invested capital is computed as after-tax operating earnings divided by year-end total debt plus shareholders' equity; the trend — a 380 basis-point decline from fiscal 2021 to fiscal 2025 — is the cleanest quantitative summary of the acquisition-intensity question, and is best read alongside the goodwill-and-intangibles ratio, which reached 49.8% of total assets at year-end 2025.

Cash conversion cycle. Approximate FY2025 values: days inventory outstanding approximately 171 days; days sales outstanding approximately 66 days; days payables outstanding approximately 145 days; cash conversion cycle approximately 92 days. These are derived using estimated year-end trade receivables and should be confirmed against the FY2025 balance sheet detail. Inventory days have risen materially since fiscal 2021, consistent with the disclosed increase in inventories from USD 10.4 billion to USD 14.2 billion.

6.7 Fiscal 2026 interim performance

Zero entries denote figures not captured in this review rather than nil values. H1 2026 pre-tax earnings of USD 12.7 billion (25.8% of sales) compare with USD 20.1 billion (44.1%) in H1 2025, the difference being the prior-year USD 7.0 billion talc reversal. Q1 2026 operating cash flow was USD 2,514 million; dividends paid USD 3,131 million; share repurchases USD 4,028 million; cash and equivalents USD 21,688 million at 29 March 2026.

22.1 Management guidance

For fiscal 2026, following the 29 July 2026 revision for the Firefly and Sail transactions:

Guidance is calculated at a euro average rate of USD 1.15. Fiscal 2026 contains a 53rd week, weighting Q4. Beyond 2026, management has consistently reaffirmed a line of sight to double-digit revenue growth by the end of the decade. The next scheduled forum for medium-term targets is the Enterprise Business Review on 8 December 2026.

22.2 Consensus expectations

Consensus is clustered around the guided sales figure of roughly USD 101 billion for 2026, with EPS estimates in the process of resetting following the 29 July guidance revision. The twelve-month price target range across providers is USD 257.50 to USD 305, with the most commonly cited averages at USD 267–273. Rating distribution is approximately 11 Buy, 13 Hold and 0 Sell — a Hold-leaning consensus at the stock's current level after a 53% twelve-month advance.

22.3 Bull case

1. The talc discount unwinds. For a decade the market has applied a valuation discount for an unquantifiable liability. A USD 5.5 billion settlement — against a company generating USD 19.7 billion of annual free cash flow and holding Aaa/AAA ratings — converts an unbounded tail risk into a defined, affordable cash obligation. If the 95% acceptance threshold is met and the settlement finalises, the discount should compress. The June 2026 expert-withdrawal ruling materially improved the company's negotiating position, which is why the settlement multiple is well below the USD 8–10 billion previously contemplated in bankruptcy.

2. The 2029 inflection is real and mechanically driven. Three separable effects converge at the end of the decade: the Genmab DARZALEX royalty of 12–20% (USD 2.4 billion in fiscal 2025) rolls off; STELARA's erosion fully annualises out of the growth base, removing what was a 1,040 basis-point drag in fiscal 2025; and the 2024–2026 launch cohort — TREMFYA in IBD, CARVYKTI, RYBREVANT FASPRO, CAPLYTA, ICOTYDE, INLEXZO, IMAAVY — scales. Excluding STELARA, the company already grew 11.5% operationally in fiscal 2025. Management's double-digit claim is arithmetic, not aspiration.

3. Portfolio surgery lifts the multiple. Removing a USD 9.3 billion business growing 1.1% at a below-segment margin mechanically raises both group growth and MedTech margin. If a sale at above USD 20 billion materialises rather than a spin, the company converts a low-return asset into deployable capital at a valuation the public market has never awarded it inside the conglomerate. Sell-side commentary has begun describing the company as the cleanest growth story in large-cap healthcare on precisely this basis.

22.4 Bear case

1. The 2026 EPS guidance cut reveals the cost of the growth story. Adjusted EPS growth for 2026 fell from 8.2% to 2.3% in a single announcement because of two transactions totalling less than USD 1.8 billion of committed cash. The fiscal 2027 dilution is guided at approximately USD 1.36 — more than 12% of the current EPS base. If the double-digit-growth ambition requires a continuous stream of such deals, reported earnings growth will remain structurally suppressed, and the company will be asking investors to underwrite platform bets (in vivo CAR-T, degrader antibody conjugates) that are years from revenue.

2. MedTech has not earned its capital and the fix is partial. Segment identifiable assets grew 62% since fiscal 2021 while segment return on assets fell from 8.19% to 4.76% and pre-tax margin from 16.2% to 12.2%. Orthopaedics removal addresses the slowest-growing piece but not the underlying issue, which is that Abiomed and Shockwave were bought at prices requiring sustained high growth to earn a return, in categories — pulsed field ablation especially — where Boston Scientific and Medtronic are competing aggressively. Group return on invested capital has fallen 380 basis points in four years, and goodwill and intangibles now represent 49.8% of total assets.

3. U.S. pricing is a one-way structural compression that the company has now contractually accepted. Price contributed −3.1% to fiscal 2025 revenue growth. Accrued rebates, returns and promotions rose 58% since fiscal 2021 against 20% as-reported revenue growth. The January 2026 MFN agreement commits to aligning U.S. prices with comparable developed markets for cash-paying patients and Medicaid; ERLEADA joins the Selected Drug list for 2028; Part D redesign shifts costs to manufacturers. The tariff exemption obtained in exchange is valuable but does not extend to MedTech, which faces approximately USD 500 million of tariff cost in 2026. Gross margin has already contracted 120 basis points.

22.5 Catalysts and monitorables — next twelve months

22.6 Analyst verdict

Johnson & Johnson enters the second half of 2026 in the strongest strategic position it has occupied in a decade, and simultaneously at the point of maximum expectation. The bull and bear cases are not, in fact, in disagreement about the facts; they disagree about what the market has already paid for.

The facts are these. The company will exceed USD 100 billion of revenue for the first time in 2026. It has resolved, subject to a 95% acceptance threshold, the litigation that has defined it externally since 2016, at a cost of roughly one quarter of one year's free cash flow. It has assembled — through USD 50 billion of acquisitions since 2022 — genuine category leadership in cardiovascular intervention and a credibly renewed pipeline in oncology, immunology and neuroscience. It retains a balance sheet that only two other U.S. corporations can match. And it has an identifiable, mechanically driven earnings inflection at the end of the decade as the Genmab royalty rolls off and STELARA's drag annualises out.

The counterweight is that the shares have already advanced 53% in twelve months and 22.9% year to date, taking the multiple to roughly 23.5x forward adjusted earnings for a business guiding to 2.3% adjusted EPS growth in 2026. The July 2026 guidance revision was the market's first clear look at the price of the growth ambition: two modest transactions cost 5.9 percentage points of guided EPS growth in a single announcement, and 2027 dilution is guided at more than 12% of the current earnings base. Meanwhile the two metrics that measure whether capital deployment is working — MedTech return on assets at 4.76% and group return on invested capital down 380 basis points since 2021 — are both moving the wrong way, and goodwill and intangibles now represent almost half of total assets.

The reasonable central case is that the double-digit-growth ambition is achievable but arrives later and lumpier than the narrative implies, and that between now and 2029 the company delivers mid-single-digit revenue growth with adjusted EPS growth suppressed by continued platform acquisition. In that scenario the shares are approximately fairly valued at current levels, which is precisely what the 13-Hold, 11-Buy, 0-Sell consensus distribution and the USD 257.50 low-consensus target are saying.

The asymmetry sits in two places. On the upside, an Orthopaedics sale above USD 20 billion rather than a spin-off would convert a persistently low-return asset into deployable capital at a valuation never awarded inside the conglomerate, and would be a genuine positive surprise. On the downside, failure to reach the 95% talc acceptance threshold would reopen an exposure the market has begun to treat as closed. Both are decidable within twelve months, and the 8 December 2026 Enterprise Business Review is the moment management must convert a repeated verbal ambition into a numbered plan. Until then, the appropriate posture is constructive on the business and disciplined on the entry price.

End of dossier.

--